CD4 and glioma: These data are in line with our in vitro RNA-seq data, where glioma undergoing ICD after PS-PDT induced a significantly stronger Th17 signature in murine DCs as compared to control (Fig. 4F) and provided support for the effect of the pharmacological inhibition of RORγt on the immunogenic potential of the DC-GL261_PS-PDT vaccine (Fig. 5B–F) and the depletion of IL-17+ CD4+ T cells in the brains of mice treated with DC-GL261_PS-PDT and GSK805 (Fig. 5G).